IDH1 and cholangiocarcinoma: Among IDH mutation inhibitors, ivosidenib demonstrated efficacy in the phase III ClarIDHy trial (NCT02989857), in which 185 patients with IDH1-mutated advanced cholangiocarcinoma previously treated with platinum-based were enrolled.